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Abstract
Moraxella catarrhalis is a Gram negative bacterium and a leading causative agent of otitis media (OM) in children. Recent
reports have provided strong evidence for the presence of high levels of matrix metalloproteinase (MMPs) in effusion fluids
from children suffering with OM, however, the precise mechanisms by which MMPs are generated are currently unknown.
We hypothesized that MMPs are secreted from macrophages in the presence of M. catarrhalis lipooligosaccharide (LOS). In
this report, we demonstrate that in vitro stimulation of murine macrophage RAW 264.7 cells with LOS leads to secretion of
MMP-9 as determined by ELISA and zymogram assays. We have also shown that inhibition of ERK1/2 and p38 kinase
completely blocked LOS induced MMP-9 production. In contrast, inhibition of JNK1/2 by the specific inhibitor SP600125
actually increased the level of expression and production of MMP-9 at both mRNA and protein levels, respectively by almost
five fold. This latter result was confirmed by knocking down JNK1/2 using siRNA. Similar results have been observed in
murine bone marrow derived macrophages in vitro. In contrast to and in parallel with the LOS-induced increased levels of
MMP-9 in the presence of SP600125, we found a corresponding dose-dependent inhibition of TIMP-1 (tissue inhibitor of
matrix metalloproteinase-1) secretion. Results of subsequent in vitro studies provided evidence that when JNK1/2 was
inhibited prior to stimulation with LOS, it significantly increased both the extent of macrophage cell migration and invasion
compared to control cells or cells treated with LOS alone. The results of these studies contribute to an increased
understanding of the underlying pathophysiology of OM with effusion in children.
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Introduction
Otitis media (OM) is the most common infectious disease in
children and is caused by infection with either virus or bacteria [1].
Until recently, Streptococcus pneumonia was recognized as the leading
causative pathogen; however, as a consequence of the introduction
of the newly developed heptavalent pneumococcal vaccine, the
microbiology of OM has changed and nontypeable Haemophilus
influenzae (NTHi) has become leading the pathogen and Moraxella
catarrhalis (M.cat) now ranks third (and accounts 15–20% of total
bacterial infections) [2], [3]. Most children (80%) experience at
least one episode of OM by their third birthday and half suffer
multiple episodes of infection [4]. The total health care costs for
OM are estimated to be $6 billion annually due to medical cost
and lost wages [5]. Similar to other Gram negative bacteria, M.cat
possesses lipooligosaccharide (LOS), found in the outer membrane
of the bacteria. The LOS is structurally distinct from typical
lipopolysaccharide (LPS). LOS consists of an oligosaccharide core
and associated lipid A without the presence of repeating O-antigen
polysaccharide side-chains that are commonly found in LPS [6],
[7], [8].
The tissue macrophage is one of the key immune cells usually
found at the site of inflammation. In response to pro-inflammatory
stimuli such as LOS, these cells produce pro-inflammatory
cytokines such as TNF-a, IL-6, nitric oxide etc. Additionally,
macrophages also play an important role in tissue damage and
tissue remodeling by secreting a variety of different matrix
metalloproteinases (MMPs), especially the highly inducible
MMP-9 [9]. MMP-9 belongs to a family of zinc- dependent
endopeptidase that functions to promote degradation of the
extracellular matrix [10]. Recently MMP-2 and MMP-9 have
been detected in patients with OM with effusion, as well as in
patients with chronic OM with effusion. [11], [12]. Regardless of
the status of OM, MMP-9 manifested activity is found in all
effusions. Recently we have shown that LOS from M.cat has the
capacity to activate human monocytes through toll like receptor 4
(TLR4) [13]. However, relatively little is known about M.cat LOS
induced pathogenicity in OM with effusions. In the same article,
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1 expression in human monocytes compared to typical E.coli LPS
[13] and concluded that these differences might be due to
structural differences between LPS and LOS. Here, we report that
LOS induced expression and secretion of MMP-9 in murine
macrophage like RAW 264.7 cells, as well as in bone marrow
derived macrophages (BMMØ). Inhibition of the activity of one of
the mitogen activated protein kinase (MAPK) member, JNK1/2,
further significantly augmented MMP-9 expression and produc-
tion at the mRNA and protein level, respectively. Simultaneously,
inhibition of JNK1/2 also inhibited tissue inhibitors of matrix
metalloproteinase-1 (TIMP-1) secretion, a natural inhibitor of
MMP-9 [14]. Finally we showed that increased production of
MMP-9 is associated with an increased rate of macrophage
cellular migration and invasion.
Materials and Methods
Materials
LOS was extracted from a clinical isolate of M. catarrhalis strain
O35E (Kindly provided by Eric Hansen, University of Texas
Southwestern Medical Center, Dallas, TX, USA) as described
earlier [15], [16]. The levels of protein and nucleic acid in purified
LOS preparation were less than 1%. Lipopolysaccharide from
E.coli 055:B5 was purchased from Sigma Chemicals (St Louis,
MO), JNK1/2 inhibitor SP600125, p38 inhibitor SB202190,
ERK1/2 inhibitor U0126, AKT inhibitor LY294002, MMP-2/
MMP-9 inhibitor (2R)-2-[(4-Biphenylylsulfonyl)amino]-3-phenyl-
propionic Acid (BiPS) were all obtained from Calbiochem (San
Diego, CA), Recombinant mouse MCSF was purchased from
R&D systems (Minneapolis, MN).
Cell Culture
The murine macrophage like cell line RAW 264.7 was
purchased from ATCC (Manassas, VA) and maintained in
DMEM medium containing 10% heat inactivated fetal bovine
serum (Gibco-BRL, Gaithersburg, MD) and antibiotics at 37uCa t
humidified condition under 5% CO2.
Isolation of mouse bone marrow derived macrophage
Female C57BL/6J (6 weeks) mice were purchased from Taconic
Farm Inc. (Germantown, NY) and maintained in specific pathogen
free condition in an animal facility in accordance with National
Institutes of Health guidelines. Bone marrow derived macrophages
were collected as described earlier [17], [18] with some
modification. In brief, mouse tibia and femur were cut at both
the end and flushed with RPMI 1640 medium containing 10%
FBS. Harvested cells were cultured in the presence of mouse
recombinant MCSF at 20 ng/ml for seven days at 37uC under 5%
CO2. Every two days, old media was replaced with new media
containing MCSF at the same concentration. At day seven,
adherent macrophages were used for further experiments. All
experiments involving mice were performed according to the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
protocols were reviewed and approved by institutional review
boards at the National Institutes of Health (Permit Number: 1158).
Zymography
Enzymatic activities of MMP-2 and MMP-9 present in culture
supernatants were determined by 10% precast gelatin zymogram
gel (Invitrogen, Carlsbad, CA). In brief, cells (1610
5/100 ml/well)
were cultured in 96 well plate with DMEM containing 0.5% FBS
and pretreated with SP600125 or other MAPK inhibitors as
indicated in figures, for 1 h before treating with LOS for 18 h.
Supernatants were collected and mixed with equal amounts of 26
SDS-sample buffer containing 125 mM Tris-Hcl, 4% SDS, 20%
glycerol and 0.001% bromophenol blue in the absence of non
reducing agent and incubated at 37uC for 10 minutes. A total of
20 ml of sample was loaded into each well. After electrophoresis,
gel was renatured by novex zymogram renaturing buffer
(Invitrogen) for 30 min, washed and incubated with novex
zymogram developing buffer (Invitrogen) for 18 h at 37uC, stained
with IRDye blue protein stain (Licor, Lincoln, NB) for 1 h and
destained with water for 2 h. Gels were then visualized and
photographs were taken using Odyssey infrared imaging system
(Licor Inc, USA).
Determination of MMP-9 and TIMP-1
The concentrations of MMP-9 and TIMP-1in culture superna-
tants collected as described above were determined using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instruction.
Real time RT-PCR
Total RNA was extracted from cells using RNeasy mini spin
column (Qiagen Sciences, Germantown, MD) according to the
manufacturer’s instruction. First-strand cDNAs were prepared
using TaqMan reverse transcriptase reagents (Applied Biosystem,
Foster city, CA) using eppendorf mastercycler (Eppendorf,
Hamburg, Germany). The reverse transcribed cDNA samples
were amplified and quantified using power SYBR green PCR
master mix using Step One real time PCR system (Applied
Biosystem) with specific primers according to the manufacturer’s
protocol. The primer sequences were used as follows: MMP-9, 5-
TCGCGTGGATAAGTTCTC-3 (Forward primer), 5-ATGG-
CAGAAATAGGCTTTGTCTTG-3 (Reverse Primer), Actin, 5-
AGCTGCGTTTTACACCCTTT-3, 5-AAGCCATGC-
CAATGTTGTCT-3. Following amplification, melting curve
analysis was performed at temperature between 60uCt o9 5 uC.
Silencing of JNK1/2 by siRNA
For knock down of JNK1/2 by siRNA, a mixture of four
nucleotides (ON-TARGET Plus SMARTpool siRNA) targeting
JNK1 and JNK2 were designed and synthesized by Dharmacon
(Thermo Fisher Scientific, Lafayette, CO) and used together for
transfection in RAW 264.7 cells using Fugene HD transfection
reagent (Roche Applied Sciences, Mannheim, Germany) accord-
ing to the manufacturer’s instruction. The sequences used for
JNK1 were 5-UAAAUACGCUGGAUAUAGC-3, 5-GUU-
CUUAUGAAGUGUGUUA-3, 5-GAAGCAAACGUGACAA-
CAA-3, 5-GAAGCAAACGUFACAACAA-3, 5-CAAGA-
GAUUUGUUAUCCAA-3 and for JNK2 were -
5CCGCAGAGUUCAUGAAGAA-3, 5-GCGGAUCUCUGUF-
FACGAA-3, 5-AAAGAGAGCAUGCGAUUGA-3, 5-GCAUU-
CAGCUFFUAUCAUU-3. In brief, 2610
5 cells were cultured in
24 well plates and different concentrations of siRNA were mixed
with Fugene HD and added to the cells. Cells were then incubated
for a total of 30 hours. At this point, the cell culture medium was
replaced with fresh culture media (contains 0.5% FCS) and cells
were then treated with various concentration of LOS for another
18 hours. Supernatants were collected and used to detect the
presence of MMP-9 by zymogram and ELISA. At the same time,
control siRNA (non target siRNA sequence is 5-UGGUUUA-
CAUGUCGACUAA -3) were used to exclude possible effect of
non-specific RNA.
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In vitro martigel invasion assays were performed using BD
BioCoat Martigel Invasion Chambers with 8 mm pore size (BD
Biosciences, Belford, MA) according to the manufacturer’s
protocol. In brief, invasion chambers were rehydrated with
DMEM medium for 2 h at 37uC. 5610
5 cells in DMEM medium
containing 10% FBS were added to the upper chamber (Insert)
and the wells contained only DMEM medium with 10% FBS
without any cells. Cells in the insert were pretreated with
SP600125 or MMP-2/MMP-9 inhibitor or both for 1 h followed
by stimulation with LOS (100 ng/ml) for 22 h. Noninvasive cells
were carefully removed using cotton swab. Cells that were
attached at the lower surface of the membrane were fixed and
stained with diff-quick stain kit (IMEB Inc, San Marcos, CA).
Three different areas were chosen randomly in each well, observed
under microscope at 6200 magnification and photographs were
taken
Statistical analysis
Statistical significance was determined by unpaired t- test and
performed using GraphPad Prism version 5.04 for Windows.
(GraphPad Software, La Jolla, California USA). Experimental
results are expressed as the mean of triplicates 6 standard
deviation in at least 3 independent experiments.
Results
Increased production of MMP-9 by macrophages in
response to LOS
The concentration and time dependent effect of LOS on MMP-
9 production by RAW 264.7 cells was examined. RAW 264.7 cells
were treated with various concentrations of LOS, or as a control,
with LPS for 18 hours. Production of MMP-9 was examined using
MMP-9 specific ELISA kits. Increased levels of MMP-9 were
detected in culture supernatants in response to LOS as little as
1 ng/ml compared to untreated cells and reached maximum levels
at concentrations of 100–1000 ng/ml of LOS (Fig. 1A). We did
not observe a significant difference in response to 100 ng/ml vs
1000 ng/ml of LOS in terms of MMP-9 production. Both E.coli
LPS and M.cat LOS stimulated approximately same levels of
MMP-9 production at concentration of 100 ng/ml. In the
following experiments, therefore, we routinely used LOS at
100 ng/ml concentration unless otherwise stated. The level of
MMP-2 remained unchanged at any concentration of LOS as
found in both zymogram and MMP-2 specific ELISA (data not
shown).
We also evaluated the time course for MMP-9 production by
RAW 264.7 cells in response to LOS in RAW 264.7 cells. At
6 hours following LOS treatment, we detected relatively little
amount of MMP-9 in culture supernatants but it was readily
detected at12 hours, reaching its peak at 24 hours with a slight but
probably not significant decrease at 48 hours (Fig. 1B). These data
indicates that LOS dose dependently triggers the production and
secretion of MMP-9 at 100 ng/ml and 24 hours being the
apparent optimal conditions.
Role of mitogen activated protein kinases (MAPK) in LOS
triggered MMP-9 production
MAPK has been established to play an important role in MMP-
9 production in different cell types [19]. The active role of MAPK
and/or PI3K in LOS induced MMP-9 production was therefore
evaluated in RAW 264.7 cells. Cells were pretreated with a specific
inhibitor of the signaling kinases p38 (SB202190), ERK1/2
(U0126), JNK1/2 (SP600125) or PI3K/AKT (LY294002) for
1 h and then treated with LOS (100 ng/ml) for 18 h. The levels of
secreted MMP-9 and MMP-2 were then detected using zymo-
graphy (Fig. 2A, upper panel). In separate studies, we have
established that, SP600125 at 10.0 mM concentration completely
inhibited LOS induced JNK1/2 activation and also none of the
inhibitors when used at these concentrations were toxic (data not
shown). LOS, at 100 ng/ml concentration, induced significant
production of MMP-9. None of the inhibitors alone stimulated the
production of detectable MMP-9. Inhibition of p38 and ERK1/2
resulted in complete abolishment of LOS-induced MMP-9
production. Somewhat surprisingly, inhibition of JNK1/2 by
SP600125 resulted in augmented secretion of MMP-9. To confirm
these findings, we purchased the same inhibitor from a second
commercial source (Biomol Inc, Plymouth Meeting, PA) and
obtained equivalent results. Inhibition of the AKT pathway had
no detectable effect on MMP-9 secretion. In addition, none of the
inhibitors tested alone or in combination had any detectable effect
on LOS-induced MMP-2 secretion. We also monitored the levels
of MMP-9 in culture supernatants using MMP-9 specific ELISA
(R&D Inc, USA) and observed significant increase of MMP-9
secretion by JNK1/2 inhibition compared to LOS alone (p,0.05)
(Fig. 2A, lower panel).
Figure 1. LOS dose-dependently increases MMP-9 secretion in
murine macrophage. A. RAW 264.7 cells were cultured in 96 well
plates at 1610
5/100 ml/well concentration and treated with LOS and
LPS with different concentration for 18 h and supernatants were
collected. Levels of MMP-9 were determined by ELISA. B. RAW 264.7
cells were seeded as above and treated with LOS at 100 ng/ml
concentration. Supernatants were collected at 6, 12, 24 and 48 hours
and MMP-9 was quantified by ELISA. Results are representative of at
least three independent experiments.
doi:10.1371/journal.pone.0037912.g001
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expression of MMP-9. Cells were pre-treated with various
concentrations of SP600125 with or without subsequent stimula-
tion with LOS for 18 hours and total RNA were then extracted
from the cells. A total 200 ng of RNA was converted to cDNA and
levels of gene expression of MMP-9 were determined by real time
PCR (Fig. 2B, lower panel). The levels of gene expression of
MMP-9 were found to be significantly increased by almost ten
folds with LOS treatment compared to untreated cells. Impor-
tantly, however, in cells that were treated with both SP600125 and
LOS, levels of MMP-9 mRNA expression were dose-dependently
increased by twenty folds and four folds compared to untreated
cells and LOS treated cells, respectively. In similar experiments,
culture supernatants were collected and enzymatic activity of
MMP-9 was detected by zymogram (Fig. 2B, upper panel).
Together, the data in this figure provide strong support for the
conclusion that the specific JNK1/2 inhibitor along with LOS
dose-dependently increases expression of MMP-9 at both the
mRNA and protein level.
Next, we examined the extents to which the results so far
obtained with the RAW 264.7 cell line would be applicable to
primary mouse macrophage. We therefore carried out studies to
assess the effect of SP600125 and LOS on MMP-9 production in
bone marrow derived macrophages (BMMØ) in vitro. BMMØ
generated as described in Materials and Methods were pretreated
with medium alone or with SP600125 at 10 mM concentrations for
1 hour followed by LOS treatment for 24–48 hours and levels of
MMP-9 were quantified in culture supernatants (Fig. 2C). There
were no significant levels of MMP-9 detected until 24 h in
response to LOS compared to untreated cells. However, inclusion
of SP600125 again resulted in increased levels of MMP-9 secretion
within 24 hours compared to LOS alone. Furthermore, relatively
robust levels of MMP-9 secretion were observed at 48 hours when
cells were treated with the JNK1/2 inhibitor and LOS compared
to LOS alone (p,0.05). It should be noted that, unlike RAW 264.7
Figure 2. Inhibition of JNK1/2 by SP600125 increases LOS induced MMP-9 production in murine macrophages. A, RAW 264.7 cells
were seeded in 96 well plate at 1610
5/100 ml/well. Cells were pretreated with AKT inhibitor LY 294002 (10 mM) and various MAPK inhibitors (ERK1/2
inhibitor U0126 (10 mM), p38 inhibitor SB202190 (10 mM) and JNK1/2 inhibitor SP600125 (10 mM) for 60 min and followed by LOS (100 ng/ml)
treatment for 18 hrs. Supernatants were collected and activity of MMP-9 and MMP-2 were detected by zymogram (upper panel) and levels of MMP-9
were determined by ELISA (lower panel). B, RAW 264.7 cells were pretreated with different concentration of JNK1/2 inhibitor (0.1 mM, 1.0 mM, 5.0 mM
and 10.0 mM) as indicated in figure followed by LOS treatment as described above. MMP-9 enzymatic activity and MMP-9 gene expression were
determined by zymogram (upper panel) and real time-PCR, respectively (lower panel). C, Bone marrow derived macrophages were again pretreated
with SP600125 (10 mM) for 1 hour followed by LOS treatment (100 ng/ml) for 48 hours. Cell culture supernatants were obtained and levels of MMP-9
were measured using ELISA kit. Typical results of three independent experiments are shown. ** (p,0.05, considered significant).
doi:10.1371/journal.pone.0037912.g002
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even in untreated samples. This is perhaps due to the fact that
primary cells were previously cultured in the presence of M-CSF
for seven days, which might lead to secretion of MMP-9 even in
the absence of LOS treatment. These data further confirm our
earlier observations and together these data provide strong
evidence for negative regulation of MMP-9 production in murine
macrophage in response to LOS by JNK1/2.
Knock down of JNK1/2 by siRNA increases MMP-9
production
Since SP600125 is a pharmacological inhibitor with preferred
specificity for JNK1/2, we cannot exclude the possibility of non-
specific inhibitory effects on other signaling pathway [20]. To
confirm our observation, therefore, we adopted an additional
approach by knocking down JNK1/2 expression using siRNA and
then treating with LOS and measuring levels of MMP-9 secretion
by ELISA as previously described (Fig. 3). In separate studies, we
found that almost 70% of total JNK1/2 expression was inhibited
by specific siRNA when used at 250 nM concentration compared
to non-target siRNA (data not shown). RAW 264.7 cells that were
transfected with siRNA against JNK1/2 and subsequently treated
with LOS, secreted significantly more MMP-9 than cells that were
transfected with non-target siRNA (NT siRNA) (p,0.05) and
similarly treated with LOS. The extent of increased production of
MMP-9 correlated approximately with the siRNA concentrations
used to knock down JNK1/2 expression. Cells that were
transfected with either siRNA for JNK1/2 alone, or with control
siRNA secreted some detectable levels of MMP-9. This is perhaps
due to the effect of transfection reagent which is based on cationic
lipid or could be non-specific effect of siRNA itself. We assume the
later since siRNA without LOS treatment dose-dependently
increased secretion of MMP-9 however, the levels of MMP-9
observed were significantly lower compared to LOS alone. The
results of this study further confirm a key role for JNK1/2 in
MMP-9 secretion in murine macrophages stimulated with LOS.
However, silencing JNK1/2 had no effect on MMP-2 production
(data not shown) providing additional supporting evidence that
JNK1/2 specifically and negatively regulates MMP-9 secretion but
not MMP-2.
Inhibition of JNK1/2 results in decreased TIMP-1 secretion
in macrophages to LOS
It is well documented that tissue inhibitors of matrix
metalloproteinaeses-1 (TIMP-1) function as a natural inhibitor of
MMPs [14]. We therefore investigated the potential role of TIMP-
1 in the observed JNK1/2 regulated MMP-9 production in
macrophages followed by LOS stimulation. RAW 264.7 cells
were, as described above, pretreated with SP600125 for 1 hour
followed by LOS treatment for 18 hours and supernatants were
collected to quantitate levels of TIMP-1 secreted in culture media
by ELISA. Inhibition of JNK1/2 by SP600125 dose dependently
decreased secretion of TIMP-1 in mouse macrophage 264.7 cells
compared to LOS alone (Fig. 4). The effects of SP600125 were
detected with as little as 100 nM of inhibitor as assessed by TIMP-
1 secretion and secretion was completely inhibited at 10.0 mM.
These data suggest a possible role of TIMP-1 in JNK1/2 regulated
augmented production of MMP-9 in response to LOS.
Inhibition of JNK1/2 increases cellular invasion and
migration
Accumulating evidence suggests a potential key role of MMPs in
cellular invasion and migration [21]. Since JNK1/2 inhibition
results in an augmented MMP-9 secretion, we hypothesized that
inhibition of JNK1/2 activity will also lead to increase invasion
and migration. To test this hypothesis, we cultured RAW 264.7
cells in a martigel invasion assay chamber with 8.0 mm pore size
and treated the cells with LOS in the presence or absence of
SP600125 or MMP-9 inhibitor for 24 hours. Few cells were found
Figure 3. Knock down of JNK1/2 by siRNA enhances secretion
of MMP-9 in RAW 264.7 cells. RAW 264.7 cells were transfected with
JNK1/2 specific siRNA at various concentration for 30 h and then
treated with LOS (100 ng/ml) for another 18 h. Supernatants were
collected and levels of MMP-9 were quantitated by ELISA. One
representative data from total of three experiments is shown. NT
siRNA, non-target siRNA. **(p,0.05, considered significant).
doi:10.1371/journal.pone.0037912.g003
Figure 4. SP600125 selectively inhibits LOS-induced secretion
of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in
macrophages. RAW 264.7 cells were seeded in a 96 well tissue culture
plate as above and pretreated with SP600125 at different concentration
for 1 h followed by LOS (100 ng/ml) treatment for 18 hrs. Supernatants
were collected and levels of TIMP-1 were determined by ELISA. Results
are representative of at least two independent experiments.
doi:10.1371/journal.pone.0037912.g004
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chamber in response to LOS treatment alone compared to
untreated cells. There were no cells either invaded or migrated to
lower chamber that could be detected when treated with
SP600125 alone. However, significantly greater number of cells
were found in the lower chamber when cells were treated with
both SP600125 and LOS compared to LOS alone (Fig. 5 A–D).
To confirm the role of MMP-9 in cellular migration and invasion,
we pretreated the cells with an MMP-2/9 inhibitor followed by
SP600125 and finally with LOS. As expected, there were almost
no cells detected in the lower chamber of the plate (Fig. 5E),
thereby helping to confirm our hypothesis that LOS induced
MMP-9 is one of the primary macrophage products contributing
to macrophage invasion and migration. Cells that were treated
with only LOS and MMP-2/9 inhibitor had no detectable effect
on either invasion or migration (Fig. 5F).
Discussion
Acute otitis media (AOM) or otitis media with effusions can be
broadly characterized by the accumulation of fluid and pain in the
middle ear space with or without any sign or symptoms of
infection [22]. Irrespective of sign or symptoms, sustained infection
can bring potential pathogen such as bacteria or virus from
epipharynx to the middle ear. Pathogen or its byproduct can
stimulate local mucosal cells attracting immune-effector cells,
leading to an inflammatory response that is largely responsible for
the clinical manifestations which occur in the middle ear [23]
Initially, the tympanic membrane remains intact, however, as the
disease progresses, the structure of tympanic membrane changes
due to degradation of structural macromolecules of connective
tissues [24], [25]. These changes in the tympanic membrane
impact the overall hearing function. There are several mechanisms
proposed for this degradation and it is now well known that
MMPs, tissue plasmin and other proteases play a critical role for
the degradation of tympanic membrane [26]. Recently it has been
found that cultured tympanic membrane expresses MMPs in
response to bacterial inflammatory mediators including endotoxins
and high level of MMPs were also found in acute post
tympanostomy otorrhea (APTO) in human [27], [28]. These
evidences strongly suggest that there is a direct link between
infection and expression and secretion of MMPs which, if over-
produced, can be destructive to tissue and may contribute to the
pathogenicity of OM. LOS is one of the key virulence factors
associated with M.Cat and structurally quite distinct from typical
LPS structure [29], [6], [8]. Despite these structural differences,
both LOS and LPS have the similar capacity of cellular activation;
at least in terms of MMP-9 production in murine macrophages
(Fig. 1).
Mitogen activated protein kinases (MAPK) are protein Ser/Thr
kinases that convert extracellular stimuli to intracellular signaling
[30] and regulates wide range of cellular function such as gene
expression, mitosis, metabolism, motility, survival, apoptosis and
differentiation. Although there are total of 14 MAPKs so far have
been identified, however, three of them are most widely studied (i)
extracellular signal regulated kinase 1/2 (ERK1/2), (ii) p38 MAP
kinase and (iii) c-Jun N-terminal kinase 1/2 (JNK1/2). Here, in
this report, using specific inhibitors of various MAP kinases, we
observed that p38 and ERK1/2 positively regulate the secretion of
MMP-9 while PI3 kinase had no effect on MMP-9 secretion
(Fig. 2A). Similar results have been reported earlier that showed
activation of p38 was necessary in LPS induced MMP-9 secretion
in murine macrophage [31]. In our study, inhibition of JNK1/2
not only increased MMP-9 secretion in murine cell line but also
from bone marrow derived macrophages (Fig. 2C) suggesting that
augmented MMP-9 secretion is not unique to RAW 264.7 cell but
also applicable to mouse primary cells.
MMPs are produced in an inactive form and their activities are
regulated by endogenous inhibitor such as tissue inhibitors of
metalloproteinases (TIMPs) and disruption of the MMP-TIMP
balance can result in a number of pathogenic processes including
tumor invasion, metastasis, angiogenesis and wound healing [14].
Our data indicates that LOS augmented levels of secretion of both
MMP-9 and TIMP-1, this is perhaps due to the fact that synthesis
of MMP-9 and TIMP-1 are under the control of same
transcription factors such as AP-1, CREB and NF-kB and all
these factors can be activated by LOS [32]. Since, inhibition of
JNK1/2 by SP600125 inhibited LOS induced TIMP-1 secretion,
it is possible, at least partially, that augmented production of
MMP-9 is due to inhibition of TIMP-1 secretion. The other
possible mechanism might be at transcription level since inhibition
of JNK1/2 also increased levels of MMP-9 gene expression (Fig. 2).
The exact mechanism on how SP600125 augments MMP-9
secretion needs further investigation. It is now well documented
that MMPs are responsible for tissue invasion and angiogenesis.
MMP-2 and MMP-9 are not only found in OM with effusion but
also in pediatric patients with cholesteatoma, a chronic stage of
otitis media [11], [12], [33]. Consistent with other clinical studies,
we found strong correlation between MMP-9 secretion and
transwell migration and invasion (Fig. 5) by murine macrophage
in response to LOS together with JNK1/2 inhibition.
In summary, in this report, we have provided strong evidences
that LOS, a key virulence factor of M.cat, induced MMP-9 but not
MMP-2 secretion in murine macrophage RAW 264.7 cells.
Inhibition of JNK1/2 by SP600125 further augmented LOS
induced MMP-9 secretion in both RAW 264.7 cells and bone
marrow derived primary macrophages which in turn lead to
increased cellular invasion and migration. In past several years,
pharmaceutical companies have been developing small molecules
targeting JNK1/2 signaling pathway to treat various diseases such
as cancer, Alzheimer, ischemia-reperfusion injury and wound
healing [34]. However, contradictory results have been reported in
I/R injury animal model using SP600125. Three independent
groups reported that SP600125 reduces I/R injury in the brain
Figure 5. LOS induced MMP-9 is the key molecule responsible
for macrophage invasion. RAW 264.7 cells were cultured in martigel
invasion chamber (8.0 mM pore size) and treated with LOS and
SP600125 as described in materials and methods. After 18 h of
incubation, upper surface cells were removed and cells migrated to
lower surface were stained with H&E and observed under microscope.
A, untreated, B, LOS (100 ng/ml), C, SP600125 (10 mM), D,
LOS+SP600125, E, LOS+MMP-9 inhibitor, F, LOS+SP600125+MMP-9
inhibitor. Magnification 6200. Typical results of three independent
experiments are shown.
doi:10.1371/journal.pone.0037912.g005
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[35], [36], [37] while lee et. al. reported harmful effect of
SP600125, showing that administration of this compound
increases serum ALT level 24 hours after reperfusion with more
severe parenchymal destruction, leukocyte infiltration and MMP-9
secretion [38]. More recently, Allan F. Ryan and his group found
that SP600125 significantly inhibited mucosal hyperplasia during
in vivo bacterial otitis media in guinea pigs [39]. More studies are
needed to develop effective JNK1/2 inhibitor as a therapeutic
target to treat various diseases including OM.
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